Company intelligence / Profile preview

Somne

Barcelona/Montcada i Reixac, Catalonia, Spainsomne.co.uk ↗

Ownership: Private
Development stage: Other

Overview

SOM Biotech has demonstrated clinical proof-of-concept for its AI-driven drug repurposing approach with two programs achieving positive Phase 2 results. The lead asset, SOM3355 for Huntington’s chorea, completed a successful Phase 2b trial showing robust improvements in movement symptoms with a favorable safety profile. Other assets have reached preclinical or early clinical stages targeting various rare/orphan CNS disorders.

Therapeutic areas: Metabolic DisordersRare DiseasesNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Nippon Chemiphar (Japan)Argon PharmaCorino Therapeutics Inc.

Beyond the preview

Go deeper on Somne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Somne.

Explore the full profile